학술논문
Long-term safety and efficacy of lumacaftor–ivacaftor therapy in children aged 6–11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study
Document Type
Article
Author
Source
In The Lancet Respiratory Medicine July 2021 9(7):721-732
Subject
Language
ISSN
2213-2600